2023/24 Announcement of full-year financial results 1 October 2023 - 30 September 2024 Coloplast delivered Q4 organic growth of 8% and an EBIT margin 1 of 26%, which was negatively impacted by extraordinary costs and currencies. Reported revenue in DKK grew 12% with 3%-pts contribution from the Kerecis acquisition (two months). FY 2023/24 organic growth of 8% and 27% EBIT margin 1. Reported revenue in DKK grew 10% to DKK 27,030 million. FY 2024/25 guidance of 8-9% organic growth and an EBIT margin before special items of around 28%. "We deliver a solid full-year result in line with our financial guidance. I want to highlight our strong, broad-based performance in Chronic Care with a solid contribution from our new intermittent catheter platform Luja™, which has been our most successful launch in Continence Care to date. We also saw improved growth in the US in our fourth quarter, benefiting from the now resolved supply disruptions, which have, however, had an impact on our margin.